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In describing what is new in the management of
malignant brain tumors, I shall confine myself largely
to chemotherapy and shall outline what we think is
important based on our own experience, what we
have achieved with single and multiple agents, and
where we are going. We have just reviewed our fiveyear experience and find that chemotherapy, perhaps,
is the only thing that is new.
The development of drugs since 1943 has been
escalating at a fantastic rate. Today, we can provide
the chemotherapist with a wide array of drugs from
which to choose.
Several neoplastic diseases are now recognized
as being highly responsive to chemotherapy and the
list is growing. The first to be recognized was
childhood lymphocytic leukemia, then choriocarcinoma, and now testicular carcinoma and Wilm's
tumor.
The first consideration for effective brain tumor
chemotherapy, as we see it, is that the agent must
have optimum lipid solubility or a special transport
system . We are convinced that it must penetrate the
normal brain to be truly effective, and I shall indicate
our reasoning below.
One must achieve an adequate drug level in
brain adjacent to the tumor with minimal or no
neural toxicity, and the drug must be given frequently
enough to produce maximal DNA damage with insufficient time for repair. At the present time, we are
studying the rate of DNA damage and repair in a
search for combinations of drugs that will give less
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than added tox1c1ty and, at the same time, will
produce synergistic antitumor effects.
A water soluble compound is excluded by the intact blood-brain barrier and, administered intravenously, the drug attains a high concentration
only in the leaky, central portion of the tumor. As the
drug moves toward ventricular and subarachnoid
cerebral spinal fluid (CSF), the concentration falls
very rapidly, so that the active periphery of the tumor
is exposed to low concentrations of its drug and for a
brief time orily. If one gives a water-soluble drug in
the CSF, however, it moves quickly across the ependyma into adjacent brain. It does not exit from the
normal brain but diffuses through brain into tumor.
This would be a reasonable way, then, to give a
water-soluble drug.
On the other hand, if one uses a lipid-soluble
agent, for example, the nitrosoureas, it crosses
capillaries in the normal brain. Obviously, it crosses
the tumor's leaky capillaries, so that one has equal
drug concentrations in brain adjacent to tumor and
in tumor. If one injects a lipid-soluble drug into the
ventricle, it crosses the ependyma, instantly goes out
through the capillaries of the normal brain, and none
of it ever reaches the tumor, unless it happens to be
very close. It would be irrational to use a lipid-soluble
drug intrathecally. With lipid-soluble compounds,
concentration in the tumor is the same as concentration in the brain. We believe that this is important
both from the theoretical standpoint and from our
own experience.
Our group is interested in developing effective
drugs and drug schedules in the laboratory and in
bringing these into clinical trials. We started out with
a rat glioma; now we have two rat gliomas and three
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mouse gliomas, which we use for drug screening. In
the past, we have used reservoirs in pups for intrathecal administration. We can perform intrathecal
injections in the rat, so that it provides a model for
therapy, either by continuous intra-arterial infusion
or by intrathecal injection. We are not limited by the
route of administration. It turns out that the models
have been extremely useful, not. only for screening
promising compounds but also for working out drug
schedules and routes for administration.
The kinetics of brain tumors are most important.
We have studied animal tumors and have completed
studies of human tumors in vivo. To summarize what
we know about a glioblastoma at the present time, we
have shown that in a glioblastoma, approximately
30% of viable cells are actively dividing and the other
70% of the cells are nondividing (nonproliferating).
The cell cycle, that is, the length of time it takes a
glioblastoma cell to go from one mitosis to two cells
at the next mitosis, is somewhere in the range of 2 112-3
days. Were it not for a very high rate of cell loss, the
volume of a glioblastoma would double in approximately one week. This is unrealistic on the basis
of clinical observation. We know that the period of
time required for the glioblastoma cell to synthesize
its DNA is about 9-10 hours and, interestingly
enough, it takes an astrocytoma the same period of
time.
In our studies, we have used radioactive
thymidine, labelled either with tritium or with 14 C.
We have documented the intense proliferation seen in
blood vessels within a glioblastoma. In all probability, the limiting factor in the growth rate of a
glioblastoma is the rate at which the blood vessels can
proliferate, because there is good reason to believe
that the capillary endothelium cannot divide as rapidly as tumor cells. In brain adjacent tumor, in
the absence of tumor cells, because of tumor
angiogenesis factor, blood vessels proliferate in advance of invasive tumor.
The brain presents a particular problem . After
treatment with an effective chemotherapeutic agent, a
dead cell takes up approximately twice as much room
as living cell. The result is an increment of edema or
swelling of tumor cells and an increase in volume.
This increased volume can be detrimental because of
the effects of an increase in intracranial pressure.
Dead cells must be removed; although these cells are
now nonviable, they are still present and therefore act
as a mass. We have just completed studies on deadcell removal and have shown that when one puts
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tagged, lethally irradiated cells in brain, muscle, and
subcutaneously, brain has a most inefficient, sluggish
means of dead-cell disposal. We are convinced, both
from pathological studies as well as our own observations, that the brain is relatively inefficient in
removing dead cells as opposed to other solid organs.
At this period, we often have to use steroids to combat increased intracranial pressure and the question
arises as to what steroids do to tumors?
Methyl prednisolone or any of the glucocorticoids will increase the survival of tumor-bearing
animals that receive the steroids. Thus, you can increase the survival of a rat bearing a glioma by giving steroids. If one has a control group and a group
treated with methyl prednisolone, and they are killed
at the same time (in this instance on the 21st day) one
finds that the tumors in the control animals vary
pretty widely but •have a mean weight of 157 mg,
whereas the tumors of the animals receiving steroids
are much smaller with a mean weight of 36 mg. One
can explain this difference in two ways-steroids kill
tumor cells and steroids slow down the rate of cell
proliferation. We now have evidence that the latter is
true. There is no direct oncolytic effect on glial
tumors, but the steroid simply puts certain
proliferating cells into a nonproliferating state, and it
also increases the period of time necessary for a cell
to divide, that is, the cell cycle time. This became very
important when we checked our own clinical
statistics. Were we confusing ourselves in judging
drugs by the concomitant use of steroids? To answer
the question, we took consecutive patients. One
group of patients never received steroids. With an approximately equal number of patients in both groups,
we determined how many were chemotherapy
responders, probable responders and nonresponders.
The concomitant use of steroids did not change the
frequency of response to chemotherapy. We have
concluded that steroids have one major effect in the
brain tumor patient, that of reducing cerebral edema.
To date, we have no clinical evidence that they have
any effect on tumor cells.
The material that I intend to present is based on
a particular group of patients. These are patients who
either have tumors recurrent following surgery and
radiation therapy or in whom the diagnosis of a
malignant tumor could be made without any
reasonable doubt and whom we elect to treat by
chemotherapy rather than by radiation therapy. In
the latter group, we do not insist upon a tissue
diagnosis, feeling that the price of obtaining a tissue
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diagnosis is to justify the biopsy of a glioblastoma or
a brain stem glioma . For reasons that I shall point
out, this is more often the case.
Consequently, patients who are eligible for our
Phase II trials are those either with recurrent tumors
or with primary tumors who are considered candidates for primary chemotherapy without surgical
verification. In addition, we treat a small number of
patients with metastatic tumors. A phase II trial asks
one question: Is the drug effective, that is, does this
drug have some activity against the tumor? It asks
neither what the cure rate is nor for how long . A
phase II study is designed solely for searching out and
identifying effective drugs. For a patient to be eligible
for this kind of study, he must first be ineligible for
other studies in our program. Second, with a
pathological diagnosis or an unequivocal radiographic and clinical picture, . the patient is deteriorating neurologically. Third, if radiotherapy
has been given, it must have been completed at least
three months prior to chemotherapy. Dead cells hang
around after the completion of radiotherapy, and late
improvement can occur following radiotherapy. As a
matter of fact, since we have instituted this rule, we
have actually confirmed delayed improvement up to
three months after radiotherapy. Finally, the patient
is expected to live at least two months, and we are
sometimes wrong on that estimate, but the patient, or
more often his family, understands the complications
of chemotherapy. Parenthetically, I can say that we
have lost approximately 1% of our patients as a direct
result of complications of chemotherapy; our morbidity has been higher. Mortality has remained low
because we have means of rescuing the patient who
gets thrombocytopenia or leukopenia.
Thirty-four patients were not treated because: 1)
we found no evidence of tumor regrowth, 2) we
thought that they would live less than two months, 3)
they declined treatment after understanding it, or 4)
further surgery was elected. In the latter category, a
benign fourth ventricle cyst was referred to us as a
recurrent brain stem glioma, and we sent the patient
back with diagnostic studies to the referring
neurosurgeon who removed the cyst. Recently, I
removed a nerve sheath tumor of the tenth nerve
which had been misdiagnosed as a brain stem glioma
and, after radiation therapy, was sent to us for
chemotherapy. We have seen a ·variety of misdiagnosed lesions, emphasizing the need for careful study.
In one patient, we thought radiotherapy was the
treatment of choice.
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To judge the effect of chemotherapy, we use two
criteria. We have a third which will probably be
added-the EEG (which came as a complete surprise
to me). At first, I would not allow our electroencephalographer to charge our patients, because I
was convinced that EEG would be valueless, but it
did just about as well as a scan in predicting whether
a patient was better or worse. We, like others, will be
looking to the EMI scanner for a fourth criterion .
The two criteria on which our data are based are the
clinical status and the brain scan . A patient classed as
a responder is better clinically and his brain scan is
better. A patient is designated a probable responder if
clinical status is: 1) improved and the brain scan is the
same, 2) if the clinical status is the same and the brain
scan is better, or 3) if both of them remain the same
for at least three months in the case of medulloblastomas and glioblastomas and six months
for more benign tumors. A nonresponder deteriorates as judged by clinical status and brain scan.
A certain number of patients in our series were
nonevaluable. We determined, in retrospect, that
patients surviving for less than two months after
beginning treatment were not evaluable-again,
because of the slow removal of dead cells. Approximately 15% of all responders were considered
failures when they returned for their second course of
therapy. If a patient receiving a course of
chemotherapy is obviously worse six weeks later, it
does not mea n that the drug is ineffective, because
among those patients who eventually turn out to be
unequivocable responders, 15% have had an initial
deterioration in brain scan and clinical condition .
Several patients were nonevaluable because, in the
beginning, we were inexperienced . In some, the
neurological condition was not clearly deteriorating
immediately prior to treatment; others failed to complete one full course; and on five patients, we were
unable to obtain an adequate follow-up.
What can we expect in using single drugs? With
BCNU (still the best single drug used to date), 27 of
our 57 patients showed a response, a rate of 47% over
a mean duration of nine months, and this a population of recurrent tumors . CCNU has a response rate
of 44% but for a shorter mean duration. Procarbazine, also a powerful drug with a 52% response
rate, has a mean duration of six months. We are unable to give an explanation for the fact that when we
combine BCNU and vincristine (which should be a
good combination because vincristine is not toxic to
the bone marrow), we get a respon se rate of only 45%
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over four months. Although BCNU and CCNU are
virtually identical and both are highly lipid soluble,
BCNU seems to have a clear advantage. Procarbazine
is not lipid soluble, but it does proceed rapidly, in
high concentration, into CXF. The three most effective single agents, thus, have in common bone
marrow toxicity and very rapid entry into brain and
into CSF.
What of the patient who receives a first drug
and, whether with or without response, then proceeds
with a second drug? A response to a second drug is
very small, probably for two reasons-one, a possible
cross resistance and two, by the time of proceeding to
a second drug, the patient is usually in poor
condition.
What can be said of tumor types as related to
specific drugs? With malignant gliomas and
astrocytomas or glioblastomas, the response is
similar with all of the three most effective drugs. For
ependymomas, BCNU is extremely good, one of our
patients responding to BCNU as the second drug administered. The other tumor-specific chemotherapy,
which I shall go into later, is the combination of
procarbazine, CCNU, and vincristine that seems to
be highly effective for medulloblastomas.
As must be well known, BCNU is given intravenously on various schedules; it is quite likely
that we do not use the optimal schedule. One of our
early patients, a quadriplegic with an ependymoma,
had a fantastic response over several months to
BCNU, but ultimately could not receive any more
due to the development of cumulative bone marrow
toxicity. One patient with a malignant astrocytoma,
having been treated with BCNU for two years, shows
no evidence of tumor regrowth after two and one-half
years off treatment. One young boy, who had a
recurrent ependymoma of the fourth ventricle with
supratentorial metastases, tumor cells in his CSF,
and recurrent tumor in his posterior fossa, was
treated with BCNU for two and one-half years; he is
attending college now with no evidence of recurrent
disease after two years off treatment.
The Brain Tumor Study Group has studied
BCNU in a phase III trial, taking patients who had
had a major craniotomy and removal of a supratentorial glioblastoma. Postoperatively, these patients
were not dependent upon steroids and they randomized within three weeks of operation; thus, this is
a select group of patients treated in the early
postoperative period. Patients who received no
further treatment had a median survival of 15
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weeks-a little less than four months, which seems to
be a little on the low side. Those patients who received only BCNU postoperatively had a median survival of 21 weeks; those who received irradiation
therapy had a median survival of 30 weeks; and those
receiving BCNU plus irradiation had a median survival of 40 weeks. How do we interpret this? Irradiation and BCNU combined are better than either
alone and better than no further treatment after surgery as well. Of the various forms of adjuvant therapy
reported for glioblastomas, the most effective is
BCNU and irradiation combined following major
tumor removal. At the time of this study, about four
years ago, BCNU was used because it had been
shown to be an active drug in phase II trials.
One of the people in our laboratory became an
expert at removing rat gliomas, and we evaluated adjuvant chemotherapy and surgery, using a rat brain
tumor model. We asked: Are we giving BCNU at the
right time? Should it be given before operation, with
the operation, or afterwards? We tried various combinations of BCNU and surgery and in one group, we
even added 5-FU to obtain early proliferating
postoperative cells. The study showed that there was
no combination of surgery and BCNU that was as
beneficial as BCNU alone. I could not believe it and
we repeated the experiments four times. The experiments defied my prejudice and the basic laws of
cell kinetics, and the results have now been submitted
for publication. I do not believe, however, that on
this basis, neurosurgeons will stop removing
glioblastomas, but we did feel encouraged to treat a
few human glioblastomas, diagnosed angiographically without histological verification. Of the patients treated in this way, only two harbored primary reticulum cell sarcomas that we called
glioblastomas-not a large error.
Procarbazine is a monoamine oxidase inhibitor
and patients under treatment, therefore, cannot eat
ripe cheese or take certain drugs. One patient, who
showed excellent results by brain scan, became
irreversibly psychotic, so it is not a perfect drug, but
it does move rapidly into the CSF. In one of our first
patients, with a recurrent medulloblastoma and a
total spinal block, procarbazine alone melted away
the mass. Though active against medulloblastomas,
procarbazine alone is not as active as a more recent
drug combination to be mentioned below. Its activity
against malignant gliomas is similar to BCNU.
Single drug therapy for solid tumors is rarely
curative in animal or human systems after the tumor

204
reaches a clinical size. Those people interested in
solid tumors, therefore, are looking to combination
chemotherapy, using drugs that have qualitatively
different toxicity and complimentary mechanisms of
action to prevent the emergence of resistance clones,
and are combining agents that act on cycling versus
noncycling (nonproliferating) cells.
Our first multiple drug protocol involved three
drugs : CCNU, which we knew was active and could
be given by mouth; vincristine, which was active and
did not add toxicity to the bone marrow; and procarbazine, which we thought was an excellent drug. The
course was given on a 28-day cycle: CCNU on day I,
procarbazine for the first 14 days, and vincristine
twice (days I and 8). We obtained a response rate of
57% (I cannot give the median duration, but it has
produced some of the most dramatic responses we
have seen with medulloblastomas.). We are now persuaded for the first time, that we have something safe
enough and effective enough to justify designing a
study of combining chemotherapy with radiotherapy
for the immediate treatment of verified medulloblastomas . Our response rate here has been
well over 75%, but the patients do develop chronic
bone marrow toxicity. For example, a little girl who
came in with papilledema and huge subfrontal
metastases had a normal brain scan two months ago,
after receiving procarbazine, CCNU, and vincristine,
but due to chronically depressed bone marrow, we
are unable to give her more drug and she is experiencing a recurrence.
We tried the combination of Cytoxan®
(cyclophosphamide), CCNU, and vincristine. We
saw few responses and concluded that this is not an
effective combination.

WILSON: MALIGNANT BRAIN TUMORS

What are the approaches to more effective
chemotherapy? We are convinced that drug combinations are the wave of the future. Simultaneously,
we are trying to identify new effective single drugs
and effective combinations of single drugs. We are
now actually putting into practice schedules based on
kinetic information, that is, cell cycle and number or
percentage of proliferating cells. It may be possible to
convert tumor cells that are nonproliferating into a
proliferating state in which they are more susceptible
to drugs specifically damaging to proliferating cells.
Possibly, we can convert some normal cells, such
as gut and bone marrow, from their normal
proliferating state to a noncycling compartment, particularly bone marrow, so that it will not be
devastated by the drugs we use. We do not have a
single drug today that is specific for cancer cells and
are always on a tight wire between poisoning the host
and poisoning the cancer.
We hear a great deal about enhancing immune
mechanisms. In the one reported study, patients who
were immunized did no better than those who were
not. There are some very promising things on the
horizon, but at the moment, I see no immediate role
for immunotherapy. The successful acceleration of
dead cell disposal, in which we are extremely interested, will have some practical application.
In summary, our studies have identified three
agents individually active against a variety of brain
tumors. Procarbazine belongs in another pharmacological group, but BCNU and CCNU are
similar. Combination chemotherapy holds great
promise for brain tumor chemotherapy, and one of
the two combinations evaluated by us is highly effective against medulloblastomas.

